Title: MMWR Vol. 59 / No. RR-11
| If you have trouble reading this e-mail, please click here.
|
|
|
Recommendations and Reports
Volume 59, No. RR-11
December 10, 2010
|
|
|
|
|
Prevention of Pneumococcal Disease Among Infants and Children — Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine
Recommendations of the Advisory Committee on Immunization Practices (ACIP)
|
|
|
|
|
On February 24, 2010, a new 13-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV13) (Prevnar13, Wyeth) was approved by the Food and Drug Administration for prevention of invasive pneumococcal disease in children aged 6 weeks–71 months. PCV13 replaces the previous 7-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV7).
This report summarizes recommendations approved by the Advisory Committee on Immunization Practices on February 24, 2010, for the prevention of pneumococcal disease among infants and children aged <18 years and replaces previous ACIP recommendations for preventing pneumococcal disease in children. It also provides updated information regarding changes in the epidemiology of pneumococcal disease in the United States since routine PCV7 infant vaccination began in 2000.
|
|
 full text
|
|
|
|
Department of Health and Human Services
Centers for Disease Control and Prevention
|
|
|
Modify/Update Subscriber Preferences | Unsubscribe | Send Feedback | Learn more about CDC Email Updates
To receive the latest news for your region, please update your profile with your country, state and zip code.
Questions or problems? Please contact support@xxxxxxxxxxxxxxx.
Centers for Disease Control and Prevention (CDC) · 1600 Clifton Rd · Atlanta GA 30333 · 800-CDC-INFO (800-232-4636)
